Migraine Clinical Trial
Official title:
Salivary Inflammatory Markers (Interleukin -1β, Interleukin -6, C- Reactive Protein) in Tension Type Headache and Migraine
Data role of salivary inflammatory markers in migraine and Tension Type headache (TTH) are lacking. Τhe investigators studied whether headache attacks are associated with changes in C reactive protein (CRP), Interleukin -1β and Interleukin -6 in saliva in patients with Tension Type Headache and Migraine and age matched healthy controls . Τhe investigators, also investigated whether these markers could be influenced by comorbidities such as depression and anxiety.
Sixty subjects of both genders, aged from 18 to 60 years old, with primary headaches TTH and
migraine, according to the International Classification of Headache Disorders, 3rd edition
(beta version), were enrolled from the outpatient headache clinic of University Hospital of
Athens between January to March 2016. 30 healthy control subjects aged matched were recruited
mainly from hospital staff and patients' relatives.
Initially, the participants completed the Hamilton Anxiety (HAM-A), Scale Beck Depression
Inventory (BDI). All patients had to keep a headache diary during the four-week run-in
period. All headache suffers were instructed to collected salivary headache-free baseline
samples at the time of study screening when they had been free of headache for at least 48
hours (time point A). All headache suffers collected additional samples during
moderate/severe headache (time point B), and at self-defined resolution phase 24 hours of
their headache attack (time point C). Healthy control subjects were instructed to collected
samples at the time of study screening (time point D). Every week, until four weeks and one
month after the end of the study, participants were contacted, in order to ensure the
compliance and the appropriate use of the technique. One year later longitudinal data would
also be obtain.
Saliva Sample Collection Detailed instructions for the correct collection of saliva samples
were given to all participants. Such instructions include avoiding eating a major meal and
teeth brushing 60 minutes prior to sample collection. Also consumption of high sugar and
caffeine content foods as well as high acidity foods have to be excluded before saliva sample
collection. Mouth rinse with water in order to remove any food residue and saliva sample
collection at least 10 minutes after mouth rinse was recommended. Unstimulated whole saliva
that pooled on the mouth floor were collected from patients and healthy volunteers in high
quality polypropylene vials by the passive drool technique. Finally, all samples were stored
in a plastic container at 2-4 ° C until analysis. Saliva was collected from the participants,
at 8.00 a.m. in the morning in order to rule out any confounding factor caused by circadian
rhythm.
Sample Analysis Morning samples were kept in the refrigerator at 4°C and at the end of the
day were brought to the laboratory where they were centrifuged 3000 rpm at 4°C and the
supernatant was aliquoted in to polypropylene Cryogenic vials. Vials were frozen in -80°C
until analyzed. Saliva transferrin levels were measured by competitive immunoassay kits and
Interleukin-6, Interleukin-1β and CRP levels were measured by sandwich ELISA kits.
Transferrin levels were used as a screening tool for the presence of blood in saliva samples
and samples with transferrin values greater than 1 mg/dl were considered as candidates for
exclusion in other salivary assays. Cortisol assay has a sensitivity of < 0.007 μg/ml and an
inter-assay coefficient of variation of < 11% while these characteristics are 0.07 pg/ml and
8 for Interleukin-6, 0.37 pg/ml and 7 for Interleukin-1β, 10 pg/ml and 11.2 for CRP as well
as 0.08 mg/dl and 7.2 for transferrin respectively.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |